1. Home
  2. VTYX

as 03-28-2025 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Medicinal Chemicals and Botanical Products

Nasdaq

Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.

Founded: 2018 Country:
United States
United States
Employees: N/A City: SAN DIEGO
Market Cap: 154.9M IPO Year: 2021
Target Price: $11.33 AVG Volume (30 days): 733.5K
Analyst Decision: Buy Number of Analysts: 4
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -1.97 EPS Growth: N/A
52 Week Low/High: $1.17 - $5.88 Next Earning Date: 05-08-2025
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

VTYX Daily Stock ML Predictions

Share on Social Networks: